Northern Trust
MLTX icon

Northern Trust’s MoonLake Immunotherapeutics MLTX Stock Holding History

Northern Trust’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$889K Buy
45,660
+26,183
+134% +$475K ﹤0.01% 3507
2026
Q1 		$363K Buy
19,477
+998
+5% +$16.5K ﹤0.01% 3737
2025
Q4 		$244K Sell
18,479
-26,536
-59% -$313K ﹤0.01% 3911
2025
Q3 		$323K Buy
45,015
+30,701
+214% +$1.6M ﹤0.01% 3802
2025
Q2 		$676K Sell
14,314
-17
-0.1% -$693 ﹤0.01% 3551
2025
Q1 		$560K Buy
14,331
+70
+0.5% +$3.02K ﹤0.01% 3530
2024
Q4 		$772K Buy
14,261
+8,811
+162% +$450K ﹤0.01% 3503
2024
Q3 		$275K Buy
5,450
+573
+12% +$26.9K ﹤0.01% 3774
2024
Q2 		$214K Sell
4,877
-837
-15% -$35.5K ﹤0.01% 3846
2024
Q1 		$287K Sell
5,714
-1,488
-21% -$80.7K ﹤0.01% 3760
2023
Q4 		$435K Buy
7,202
+1,465
+26% +$75.5K ﹤0.01% 3581
2023
Q3 		$327K Buy
+5,737
New +$317K ﹤0.01% 3635

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Northern Trust's MLTX Position: Q2 2026 in Review

Northern Trust increased its MoonLake Immunotherapeutics (MLTX) stake by 134% in Q2 2026, buying an estimated $475K and bringing the position to 45,660 shares worth $889K. The position accounts for ﹤0.01% of the portfolio, ranked #3507.

Northern Trust first reported a position in MLTX in Q3 2023 and has held it in 12 quarters since. 173 funds tracked by Wall St. Rank hold MLTX as of Q2 2026.

  • Northern Trust held 45,660 shares of MoonLake Immunotherapeutics worth $889K as of Q2 2026.
  • Northern Trust bought 26,183 MoonLake Immunotherapeutics shares in Q2 2026, an estimated $475K.
  • MoonLake Immunotherapeutics made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3507 holding.
  • Northern Trust first reported a position in MoonLake Immunotherapeutics in Q3 2023 and has held it in 12 quarters since.
  • 173 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.